Patents Assigned to Delinia, Inc.
  • MULTIVALENT REGULATORY T CELL MODULATORS
    Publication number: 20180162919
    Abstract: This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 14, 2018
    Applicant: Delinia, Inc.
    Inventors: Jeffrey Greve, Jungmin Kim, Niranjana Nagarajan, John Cho
  • IL-2 Variants for the Treatment of Autoimmune Diseases
    Publication number: 20180125941
    Abstract: This disclosure provides for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound that comprises an IL-2 receptor-binding moiety. The methods described in the present disclosure provide enhanced pharmacokinetic profiles. The disclosure also provides methods for treating autoimmune disease comprising administering a therapeutically-effective amount of a fusion protein comprising an IL-2 variant protein.
    Type: Application
    Filed: November 8, 2017
    Publication date: May 10, 2018
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve
  • MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20180037624
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Application
    Filed: September 6, 2017
    Publication date: February 8, 2018
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve
  • MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20170327555
    Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fe protein. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fe moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
    Type: Application
    Filed: July 28, 2017
    Publication date: November 16, 2017
    Applicant: Delinia, Inc.
    Inventor: Jeffrey Greve